EcoDrugPlus

Calcium Voltage-Gated Channel Auxiliary Subunit Gamma 5

Ensembl ID : ENSCLAG00000004248
Gene Symbol: CACNG5
2 Cross references
251 Possible Orthologues:

Calcium Voltage-Gated Channel Auxiliary Subunit Gamma 6

Ensembl ID : ENSCLAG00000002011
Gene Symbol: CACNG6
2 Cross references
248 Possible Orthologues:

Calcium Voltage-Gated Channel Auxiliary Subunit Gamma 7

Ensembl ID : ENSCLAG00000000679
Gene Symbol: CACNG7
2 Cross references
257 Possible Orthologues:

Calcium Voltage-Gated Channel Auxiliary Subunit Gamma 8

Ensembl ID : ENSCLAG00000000968
Gene Symbol: CACNG8
1 Cross references
243 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 A

Ensembl ID : ENSCLAG00000013282
Gene Symbol: CACNA1A
2 Cross references
269 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 B

Ensembl ID : ENSCLAG00000006876
Gene Symbol: CACNA1B
2 Cross references
284 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 C

Ensembl ID : ENSCLAG00000014730
Gene Symbol: CACNA1C
2 Cross references
212 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 D

Ensembl ID : ENSCLAG00000008239
Gene Symbol: CACNA1D
2 Cross references
280 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 E

Ensembl ID : ENSCLAG00000010910
Gene Symbol: CACNA1E
2 Cross references
295 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 F

Ensembl ID : ENSCLAG00000002756
Gene Symbol: CACNA1F
3 Cross references
176 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 G

Ensembl ID : ENSCLAG00000013164
Gene Symbol: CACNA1G
3 Cross references
198 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 H

Ensembl ID : ENSCLAG00000013993
Gene Symbol: CACNA1H
2 Cross references
213 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).